Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4539-3 ◽

2017 ◽

Vol 167 (1) ◽

pp. 407-407

Author(s):

Carlo Palmieri ◽

◽

Rob C. Stein ◽

Xinxue Liu ◽

Emma Hudson ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Steroid Sulfatase ◽

Breast Cancer Patients ◽

Er Positive ◽

Positive Breast Cancer

Download Full-text

IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4328-z ◽

2017 ◽

Vol 165 (2) ◽

pp. 343-353 ◽

Author(s):

Carlo Palmieri ◽

◽

Rob C. Stein ◽

Xinxue Liu ◽

Emma Hudson ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Steroid Sulfatase ◽

Breast Cancer Patients ◽

Er Positive ◽

Positive Breast Cancer

Download Full-text

Phase II Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab

10.21236/ada471552 ◽

2007 ◽

Author(s):

Mary L. Disis

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iv ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Her 2 ◽

Domain Peptide ◽

Positive Breast Cancer

Download Full-text

Phase II Study of a HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab

10.21236/ada533841 ◽

2010 ◽

Author(s):

Mary L. Disis

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iv ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Her 2 ◽

Domain Peptide ◽

Positive Breast Cancer

Download Full-text

5062 Fulvestrant in heavily pre-treated ER-positive post-menopausal metastatic breast cancer patients: final update of a phase II study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70954-1 ◽

2009 ◽

Vol 7 (2) ◽

pp. 279

Author(s):

R. Ratti ◽

Z. Coccorullo ◽

D. Guarneri ◽

G. Addamo ◽

G. Colloca ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Er Positive ◽

Post Menopausal

Download Full-text

Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine for the treatment of meningeal metastases (NM) in HER2-positive breast cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps123 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS123-TPS123

Author(s):

J. Bischoff

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Liposomal Cytarabine ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Oral Capecitabine ◽

Positive Breast Cancer

Download Full-text

A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) – Trial Results.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.549 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 549-549 ◽

Author(s):

Carlo Palmieri ◽

Robert C. Stein ◽

Xinxue Liu ◽

Emma Hudson ◽

Sadie Reed ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Steroid Sulfatase ◽

Breast Cancer Patients ◽

Safety And Efficacy ◽

Download Full-text

Phase II Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab

10.21236/ada456015 ◽

2006 ◽

Author(s):

Mary L. Disis

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iv ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Her 2 ◽

Domain Peptide ◽

Positive Breast Cancer

Download Full-text

Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy

10.21236/ada486630 ◽

2008 ◽

Author(s):

Mary L. Disis

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Her 2 ◽

Trastuzumab Monotherapy ◽

Positive Breast Cancer

Download Full-text

Abstract OT2-2-05: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/− GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (GBG-54 MALE)

10.1158/0008-5472.sabcs12-ot2-2-05 ◽

2012 ◽

Author(s):

M Linder ◽

G von Minckwitz ◽

A Kamischke ◽

C Rudlowski ◽

H Eggemann ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Cancer Patients ◽

Phase Ii ◽

Male Breast Cancer ◽

Palliative Treatment ◽

Phase Ii Study ◽

Male Breast ◽

Gnrh Analogue ◽

Breast Cancer Patients

Download Full-text

Abstract PD7-10: Male-GBG54: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients

10.1158/1538-7445.sabcs17-pd7-10 ◽

2018 ◽

Author(s):

M Reinisch ◽

S Seiler ◽

T Hauzenberger ◽

S Schmatloch ◽

HJ Strittmatter ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Gonadotropin Releasing Hormone ◽

Endocrine Treatment ◽

Breast Cancer Patients ◽

Hormone Analogue ◽

Gonadotropin Releasing Hormone Analogue

Download Full-text